WO2006098519A1 - ピラゾロピリミジン誘導体またはその医学上許容される塩 - Google Patents
ピラゾロピリミジン誘導体またはその医学上許容される塩 Download PDFInfo
- Publication number
- WO2006098519A1 WO2006098519A1 PCT/JP2006/305896 JP2006305896W WO2006098519A1 WO 2006098519 A1 WO2006098519 A1 WO 2006098519A1 JP 2006305896 W JP2006305896 W JP 2006305896W WO 2006098519 A1 WO2006098519 A1 WO 2006098519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally substituted
- substituted
- alkyl group
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to a novel pyrazo-oral pyrimidi: / t conductor or a medically acceptable salt thereof, a medical product containing them, and MA PKAP-K 2 (mitogen-activated protein kinase activity) containing them as a ⁇ ] component Protein kinase 2) P and harmful agents and new intermediates.
- MA PKAP-K 2 mitogen-activated protein kinase activity
- the present invention also includes those compounds as 3 ⁇ 43 ⁇ 4 components, neurodegeneration and Z or nephropathy (including stigmatism), 3 ⁇ 401 ⁇ 2, self-exclusion, ruptured bone disorder, inflammation disease, Treatment for Psoriasis, Diabetes, Cancer, Ischemic Regeneration 3 ⁇ 4 ⁇ Type P Injury, Angiogenic Disorders, Cachexia, Moon Disease, Angiogenesis, Asthma, or Chronic Obstruction 141 ⁇ Disease (COPD) About.
- Psoriasis CAD
- Diabetes Cancer
- Ischemic Regeneration 3 ⁇ 4 ⁇ Type P Injury, Angiogenic Disorders, Cachexia, Moon Disease, Angiogenesis, Asthma, or Chronic Obstruction 141 ⁇ Disease (COPD) About.
- MAPKAP-K2 myregen-activated protein kinase activity proteinase 2 is a serine Z threonine kinase that operates immediately downstream of the p38 kinase in the stress-induced MAP K pathway ( Figure 1).
- the p38 kinase pathway is activated by a variety of stress-related stimuli such as heat, ultraviolet light, bacterial lipopolysaccharide, and inflammatory site forces. Activation of this results in transcription and phosphorylation of the initiation factor, affecting cell division, apoptosis, cell differentiation, inflammatory response and cell invasion (Marti 'n-B 1 anco, Bioe ss ay s 22, 6 37-645).
- stress-related stimuli such as heat, ultraviolet light, bacterial lipopolysaccharide, and inflammatory site forces.
- p38 kinase itself activates many protein kinases other than MAPKAP kinase, such as * Mn-klZ2, PRAK, and O ⁇ MS K1 ( Figure 1). This pathway is particularly important for the discovery of new anti-inflammatory drugs.
- the selective inhibitor of p38 kinase is effective in suppressing pro-inflammatory cytokines in both cell-based and chronic models of chronic inflammation (Lee et al., Immunopha rma colog.y 47, 185 -201 (2000)).
- p38 kinase knockout mice are embryonic iclet ha 1 embryonic. In addition, such an embryo-derived cell has been proven to have many abnormalities with respect to a detailed answer.
- MAPKA?-K2 enters the nucleus of innocuous I microcells and then moves to the cytoplasm when the cells are stimulated.
- This kinase is known to phosphorylate a number of nuclear transcription factors, as well as cytosolic proteins, such as heat shock proteins involved in cytoprotection and 5-lipoxy shigenase involved in ecological defense and inflammation (S t okoe et al., FEBS Le t t. 313, 307-313 (1992); Werz et al., Pro c. Natl. Ac a d. S ci.
- MAPKAP-K2 is the only ⁇ 38 kinase substrate that has been identified with special functions.
- the special role of MAPKAP-K2 in mediating the inflammatory response is MAPKAP-K
- mice can survive and are normal except that their flammability is markedly reduced.
- MAPKAP-K2 deficiency proved to provide exceptional protection of God cells from itifiLti damage (Wang et al., J. B io l. C he m. 277, 4 3968-43972 (29002))
- MAPKAP-K2 is thought to regulate the SI and Z or stability of mRNA, an important inflammatory cytokine. This is thought to be because MAP KAP-K2 phosphorylates proteins that bind to AU-rich elements found in the unaffected regions of these cytokines. The identification of these proteins is currently under study.
- MAPKAP-K2 has been reported to repair UV-induced DNA abnormalities (Isa a c A. Manke et al., Mo 1 e c u 1 a r Ce 1 117,
- MAP KAP-K2 may fail to repair DNA damage, depending on the type of cancer cell, and may die.
- MA PKAP-K 2 inhibitor IJ is a neurodegenerative and / or neurological disorder (including dementia), losing autoimmune diseases, destructive bone disorders, inflammatory diseases, diabetes mellitus, cancer Examples are ischemia report disorder, angiogenic disorder, cachexia, obesity, angiogenesis, asthma, or chronic obstructive collapse (COPD)).
- An object of the present invention is to identify a novel modification useful as MAPKAP-K2P and J.
- the object of the present invention is also a novel MAPKAP-K2 inhibitor, or a novel neurodegeneration and Z or neurological disorder (including dementia), sepsis, autoimmune disease, destructive bone disorder, inflammation 'Tt ⁇ disease, probable, diabetic, cancer, ischemia re'port current P chapter harm, angiogenic disorder, sputum, lupus, angiogenesis, asthma, or chronic closure, treatment of mania (COPD) or
- the treatment method is «.
- an object of the present invention is to provide a novel intermediate of MAPKAP-K2PIL # ⁇ .
- the present inventors have found that the novel pyrazomouth pyrimidine derivatives represented by the following formula (1) or their pharmaceutically acceptable salt power exhibits excellent MAPKAP-K2P and harm. And make the present invention 3 ⁇ 4 ⁇
- the present invention is as follows.
- R 1 represents a hydrogen atom or halogen.
- k 2 represents a hydrogen atom or halogen.
- R 3 is a hydrogen atom, an optionally substituted CI-C 8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted, a heterocyclic group, or a substituted group. It may be an aryl group of C 6 -C 14 or —OR 5 . ''
- R 6 represents an optionally substituted C 1 -C 8 alkyl group.
- n 0 or 1. However, when R 3 is —OR 5 , n represents 0.
- 'R 4 is a hydrogen atom, an optionally substituted alkyl group of CI-C8, an optionally substituted C2-C8-anolekenyl, an optionally substituted C2-C8-anolequinyl, or an optionally substituted Good C 3 -C 8 alkyl group, substituted or unsubstituted V, C 6 -C 14 aryl group, substituted or even oleocyclic group, substituted or Represents a good carbocyclic aralkyl group or a substituted C 7 -C 16 aralkyl group.
- R 4 C6 - location ⁇ 3 ⁇ 4 of Ariru group C14 are halogen, - CN, - N_ ⁇ 2, - CHO, - OH, - COOH, optionally substituted C 1 - C8
- R 26 to R 43 , R 133 , R 150 , and R 151 may be the same or different, a hydrogen atom, an optionally substituted C1-C8 alkyl group, and an optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 It may be a heterocyclic group which may be substituted, a good aralkyl group which may be substituted or a heterocyclic group which may be substituted.
- R 30 and R 31 , R ′ 32 and R 33 , R 37 and R 38 , R 42 and R 43 and R 150 and R 151 may be substituted with alkyl groups that may be bonded to each other.
- this ring may contain one or two heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a yellow atom.
- Z 1 or Z 2 may be the same or different and each represents a hydrogen atom or —CH 2 —OR 11 .
- R represents a hydrogen atom, an optionally substituted C1-C8 alkyl group or a substituted silyl group.
- R 1 represents a hydrogen atom or halogen.
- R 2 represents a hydrogen atom or halogen.
- R 3 is a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted, a heterocyclic group, an optionally substituted A good C 6 -C 14 aryl group, or -OR 5 represents.
- R 6 represents an optionally substituted C1-C8 alkyl group.
- n 0 or 1. However, when R 3 is —OR 5 , n represents 0.
- R 4 is an optionally substituted C1-C8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted C6-C14 aryl group, a substituted Represents a good ring group or an optionally substituted C 7 -C 16 aralkyl group.
- W is a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C3-C8 cycloalkynole group, an optionally substituted C6-C14 aryl group, or a substituted group.
- Represents an optionally substituted heterocyclic group, wherein m 0 to 4; or W represents an optionally substituted C 1 -C8 alkoxy group, or an optionally substituted phenoxy group.
- m l-4.
- 1 ⁇ 7 to 1 1 () and 1 127 to 1 13 ) may be the same or different, a hydrogen atom, an optionally substituted CI-C 8 ananolyl group, or an optionally substituted A C 3 -C 8 cycloalkyl group or an optionally substituted C 6 -C 14 aryl group is represented.
- R 10 and R] 27 , .R 128 and R 129 and R 130 and R 131 may be substituted for the age of the alkyl group with which they are bonded together. It forms a saturated or unsaturated 5- to 7-membered ring.
- this ring may contain one or two atom atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a ⁇ 3 ⁇ 4 ⁇ yellow atom.
- Z 3 or Z 4 may be the same or different and each represents a hydrogen atom or —CH 2 —OR 11 .
- R 11 represents a hydrogen atom or a C 1 -C 8 alkyl group.
- R1 is a hydrogen atom, the virazolip pyrimidide conductor according to ⁇ 1 > or ⁇ 2> or a medically acceptable salt thereof,
- R 2 is a hydrogen atom
- R 2 is a halogen, or a pyrazomouth pyrimidine derivative or a medically acceptable salt thereof according to any one of ⁇ 1> to ⁇ 3>,
- R 3 is an optionally substituted CI-C 8 aralkyl group, an optionally substituted C 3 -C 8 cycloalkyl group, or an optionally substituted heterocyclic group, 1> Force ⁇ Raku 5>, the villazo mouth pyrimidi as described in any of the following: ⁇ conductor or its medically acceptable salt,
- R 86 represents a C 1 -C 4 alkynole group, a C 3 -C 8 cycloanolalkyl group, or a phenol group.
- R 87 and R 88 may be the same or different and each represents a hydrogen atom, a CI-C8 anolenoquinol group, a C3-C8 cycloalkyl group, a phenyl group, or an aralkyl group.
- R 8S represents a hydrogen atom, a C 1 -C 4 alkyl group, a phenyl group, or a benzyl group.
- R 9 Represents a hydrogen atom, a C1-C4 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group.
- 1 89 9 1 9 9 () is an alkyl group: ⁇ may be combined with the nitrogen atom to which they are bonded to form a saturated or unsaturated 5- to 7-membered ring. .
- this ring may contain 1 to 2 heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom. .
- R 9 ′ is a hydrogen atom
- C 1 ⁇ C 8 represents an alkyl group, a phenyl group, or a benzyl group
- R 92 represents a hydrogen atom, a CI-C 8 anolequinolene group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group, or a benzyloxycarbonyl group.
- R 93 represents a hydrogen atom, a CI-C 8 alkyl group, a phenyl group, or a benzyl group
- R 94 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group.
- Represents a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, or a substituent in which a nitrogen atom in the heterocyclic group is substituted, is an alkyl group of CI-C 4, a benzyleno group , Acetylene group, tert-butoxynorepo 'ninole group, or benzenoreoxycanolevonyl group).
- R 3 is an unsubstituted heterocyclic group (wherein the heterocyclic group is a 5- to 8-membered ⁇ containing 1 or 2 heteroatoms selected from N, O and S) Represents a cyclic group of), a substituted saturated heterocyclic group (wherein the heterocyclic group contains 1 or 2 heteroatoms derived from N, O and S) And the substituent is a substituent of a nitrogen atom in the heterocyclic group, and represents a C1-C4 alkyl group, a benzyl group, or a tert-butoxycarbonyl group.), 1 Any one of ⁇ 1> to 5>, which is a C1-C4 alkyl group substituted with one amino group or a C3-C8 cycloalkyl group substituted with one amino group Pyrazolopyrimidine ⁇ conductor or its medically acceptable salt,
- R 3 is a cyclohexyl group substituted with a piperidyl group, a pyrrolidinyl group, or an amino group, or a pyrazo oral pyrimidine derivative according to any one of ⁇ 1> to ⁇ 5> or a medically acceptable product thereof Salt,
- R 4 is an optionally substituted C6-C 14 aryl group. salt
- R 4 is an optionally substituted C6-C14 aryl group, which is halogen, -CN, an optionally substituted C 1 -C8 alkyl group, or -O- (CH 2 ) m -W, 1> Karaku 10> key pyrazo mouth pyrimidine ⁇ ft conductor or a medically acceptable salt thereof,
- R 4 is an optionally substituted C6-C 14 aryl group, and its 3 ⁇ 4S is-O-(CH 2 ) m -W, where W is a hydrogen atom, substituted C1-C8 anoalkyl group which may be substituted, substituted or unsubstituted olefinic ring group, or optionally substituted CI-C8 alkoxy group, or any of 1> to 10> Pyrazol pyrimidine derivative or a medically acceptable salt thereof,
- R 4 is an optionally substituted C 6 -C 14 aryl group, and the substituent is halogen, —CN, an optionally substituted C 1 -C 8 alkyl group, May be a C6-C14 aryl group, or may be a substituted or heterocyclic group. Its medically acceptable salt,
- R 113 represents an optionally substituted CI-C 8 alkyl group, an optionally substituted C 3 -C 8 cycloalkenyl group, or an optionally substituted phenyl group.
- R 4 may be an optionally substituted phenyl group.
- the terminal is a single —O— (CH 2 ) m —W.
- m l-4.
- R 113 , R 118 , or R 119 may be the same or different, a hydrogen atom, an optionally substituted C1-C8 alkyl 3 ⁇ 4, an optionally substituted C3-C8 cycloalkyl Or a C6-C14 aryl group which may be substituted.
- R 118 and R 11 9 are alkyl groups: ⁇ may be combined with the nitrogen atom they form to form a saturated or unsaturated 5- to 7-membered ring, . Further, in addition to the nitrogen atom to which they are bonded, this ring may contain 1 to 2 heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a yellow atom. ), A pyrazo-oral pyrimidine conductor according to any one of ⁇ 1> to ⁇ 10> or a medically acceptable salt thereof,
- R 4 is a substituted or unsubstituted rhenic ring group, ⁇ 1> Karaku 10> Virazolopyrimidi ⁇ 3 ⁇ 4 conductor or medically acceptable salt thereof,
- R 123 represents a hydrogen atom, a C 1 -C 8 alkyl group, a phenyl group, or a benzyl group.
- R 124 is a hydrogen atom, C 1 - represents a butoxycarbonyl group or a base Nji Ruo carboxymethyl carbonylation Le group - alkyl group of C 8, benzyl group, Asechiru group, ert.
- R 122 represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a phenyl group.
- R 125 and R 126 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, a phenol group or a benzyl group.
- the nitrogen atom in the heterocyclic group is substituted, and as the substituent of 3 ⁇ 4 ⁇ , the C 1 -C 4 alkyl group, benzyl group, acetyl group, ter ⁇ -butoxycarbonyl group, or benzylo Represents a xycarbonyl group.
- R 4 is an optionally substituted dicyclic urinary aromatic ring group (wherein the bicyclic aromatic ring group is i3 ⁇ 4 from the group consisting of a phenyl group, ⁇ , ⁇ and S)
- Aromatic female ring force containing 1 or 2 heteroatoms means S-fused bicyclic aromatic ring group, or: ⁇ aromatic on the carbon atom of the heterocyclic group 3 ⁇ 4 group of ⁇ includes halogen, C1-C4 alkyl group,:! ⁇ C1-C4 alkyl group substituted by 9 halogens, 1 ⁇ 3 substituents selected from the group Alternatively, the substituent of the nitrogen atom in the heterocyclic group is substituted with a C1-C4 alkyl group. 4 Virazolopyrimidi as described here: / f
- R 4 is a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted C7-C16 aranolenoquinole A group or a substituted or substituted alkyl group, a 1> force 10> re, a pyrazomouth pyrimidine derivative or a medically acceptable salt thereof described in slip force,
- R 4 may be a substituted or unsubstituted alkyl group, or a virazolopyrimidine derivative or a medically acceptable salt thereof described in 1> Force 10>
- R] and R 2 are hydrogen atoms.
- R 1 is a hydrogen atom
- R 2 is a halogen
- R 3 is an optionally substituted CI-C8 alkyl group, an optionally substituted cyclohexyl group, or an optionally substituted cycloalkyl group (wherein the heterocyclic group Is selected from the group consisting of N, O and S:! ⁇ Means a 3-10 membered or bicyclic heterocyclic group having 4 heteroatoms ⁇ ) > Karaku 30> les, pirazoji who is masquerading in the mouth: ⁇ conductor
- R 3 is a woven heterocyclic group (wherein the heterocyclic group is a 5- to 8-membered monocyclic heterocycle containing 1 or 2 heteroatoms, which is composed of N, O and S) Represents a cyclic group)), substituted heterocyclic group (wherein the heterocyclic group is a 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S)
- the heterocyclic group is a 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S
- R 4 is an optionally substituted C1-C8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted C6-C14 alkyl group.
- R 4 is an optionally substituted phenyl group, an optionally substituted bicyclic olefinic ring group, ⁇ 28> force 32>, or the bell vilazophine pyrimidine.
- R 4 is an optionally substituted phenyl group, wherein the convertible group is-0-(CH 2 ) m-
- m Represents 2-4. 3 ⁇ 4 Represent. ⁇ , ⁇ 28> Karaku 32>, or the pyrazo-mouthed pyramid described in any of the following: conductor,
- R 4 is an optionally substituted bicyclic aromatic or unicyclic group (wherein the substituent is substituted with halogen, a C 1 -C 4 alkyl group, or 1 to 9 halogens) C 1 -C 4 alkyl group selected from the group consisting of:! ⁇ Represents the third substituent,), and villazopyrimidine derivative according to any one of 28> Karaku 32>,
- n is 0, ⁇ 28> Karaku 38> pyrazo mouth pyrimidine derivative according to any one, ⁇ 40> ⁇ 1> Karaku 27> pyrazo mouth pyrimidine derivative or any of its medicines
- COPD chronic closure disease
- Autoimmune ffi ⁇ disease is rheumatoid arthritis: ankylosing circulation, group rheumatoid arthritis, »14 arthritis, one-sided affliction, diabetes or Crohn's disease, 42 > The treatment described in lj. Brief description of the drawings.
- Figure 1 is an illustration of the p38 MAPK cascade. '' Best mode for carrying out the invention
- the compound represented by the formula (1) of the present invention is represented by the following definitions.
- an “alkyl group” refers to both a linear or branched alkyl group.
- An alkyl group having 1 to 8 carbon atoms is preferred.
- alkyl group More preferably it has 1 to 6 carbon atoms
- alkenyl group refers to a straight, branched, or cyclic alkenyl group containing one or more carbon-carbon double bonds. Both isomers are included, where these groups have cis and trans isomers. An alkenyl group having 2 to 8 carbon atoms is preferred.
- Examples include, but are not limited to, vinyl, allyl, isopropenyl, 1-propenyl, 2-butyr, 1-butenyl, 2-methinole-1-propenyl, 2-methinole-3- Penteninore, 1-Penteninore, 2-Penteninole, 4-Methinore-1-Penteninole, 1-Hexeninore, 2-Hexeninore, 2-Cyclopentenore, '2 , 2-heptul, 2-octenyl, 3-cyclopentenyl, 1, '3-'butadienyl or 1,5-hexagenino I ⁇ . More preferably, it is an alkenyl group having 2 to 6 carbon atoms.
- alkenyl group having 2 to 4 carbon atoms.
- alkenyl group examples include, but are not limited to, vinyl, allyl, isopropenyl, 1-propenyl, 2-butyl, 1-butyr, and 2-methinole-1-probenino.
- alkynyl group refers to a straight or branched alkynyl group containing one or more carbon-carbon trifis. An alkynyl group having 2 to 8 carbon atoms is preferred.
- cycloalkyl group J represents a cyclic alkyl group, preferably a cycloalkynyl group having from 3 to 8 carbon atoms.
- examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexenole, cyclin heptinole or cyclin otachino.
- a ⁇ aryl group j is an ⁇ , an aromatic hydrocarbon group having 6 to 14 bicyclic or tricyclic carbon atoms; or one per aromatic ⁇ bk.
- An aryl group having 6 to 10 carbon atoms is preferred.
- heterocyclic group J contains from 1 to 4 heteroatoms derived from the group consisting of N, O and S 3 to: 14-membered, bicyclic or tricyclic. This means a monovalent group consisting of a cyclic heterocyclic ring, which may be completely opened, partially closed, or an aromatic ⁇ -element ring group.
- the “aromatic sickle ring group” refers to the “heterocyclic group” described above, where the ring of the portion that forms a monovalent group is good! It means a cyclic or tricyclic heterocyclic group, and 3 ⁇ 4 ⁇ of a bicyclic or tricyclic heterocyclic group may be attached to ⁇ except for the ring that forms the Hffi group.
- it means a heterocyclic group S-condensed bicyclic aromatic ring group containing 1 to 4 heteroatoms, which are radically selected from the group consisting of N, O and S in the phenyl group.
- this include, but are not limited to, 4 Nazo thiazolyl, 5-benzothiazolinole, 6-benzothiazolinole, 7-benzothiazolinole, 5-benzoxazolinole, 6-benzoxazolinole , 5—Benzozinole, 6—Benzofuranole, 6—Indazolinole, 5—Quinolyl, 7—Phthalazininore, 6—Quinoxalininore, 6—Quinazolinyl, 6—Cinnolininore, 7—Chromanyl, 5—Indolinore, or 6 —Isoindolinino I ⁇ .
- it means a bicyclic aromatic ring group in which a phenyl group containing 1 or 2 heteroatoms formed from the group consisting of ⁇ , ⁇ and S is condensed with a phenyl group.
- a phenyl group containing 1 or 2 heteroatoms formed from the group consisting of ⁇ , ⁇ and S is condensed with a phenyl group.
- this include, but are not limited to, 4-benzothiazolyl, 5-benzothiazolyl,
- 6-benzothiazolyl, 7_benzothiazolinol 5-benzoxazolyl, 6-benzoxazolinole, 51-benzozenyl, 6-benzofuranyl, 6-indazolyl, 51-quinolyl,
- saturated complex difficulty refers to “heterocyclic group” described above, wherein the ring of the part forming a monovalent group is completely saturated or partially saturated.
- ⁇ # represents a bicyclic or tricyclic heterocyclic group. In the case of a bicyclic or tricyclic heterocyclic group, all but the ring that forms a monovalent group may be fully saturated, partially saturated, or good! You can be ashamed.
- Examples include, but are not limited to, monovalent groups of pyrrolidine, imidazolidine, virazolidine, monoreforin, thiomonoreforin, piperidine, homopiperidine, piperazine, homopiperazine, or tetrahydrofuran, or 3_ Chromanil, 3-Indolinino! ⁇ .
- it represents a 5- to 8-membered saturated heterocyclic group saturated with 1 or 2 heteroatoms selected from the group consisting of N, O and S.
- Examples include, but are not limited to, monovalent compounds consisting of pyrrolidine, imidazolidine, virazolidine, morpholine, thiomorpholine, piperidine; homopiberidine, piperadis homopiperazine, or tetrahydrofuran. '
- heterocyclic alkyl group J represents a group ⁇ : of a heterocyclic group and an alkyl group.
- the heterocyclic group and the alkyl group are each a“ heterocyclic group described above ”.
- alkyl group are applicable, and a description of each group and its preferred group is a preferred group.
- Examples include, but are not limited to: (2-Furyl) methyl, (3-Chenyl) methinore, (5-Isobenzofuranyl) methinore, (5-Benzoceninole) methyl, (6-Benzoxazolyl) ) Methyl, 2- (4-morpholinole) ethyl, 2- (3-phenyl) ethyl, 2- (1-pyriduryl) ethyl, 3- (2-pyridyl) propyl, or 3- (4-piperidyl) propino! ⁇ Is mentioned.
- aralkyl group refers to a group of an aryl group and an alkyl group.
- This aryl group and alkyl group correspond to the descriptions of “aryl group j and“ alkyl group ”described above, respectively.
- it is a group consisting of a “aryl group” having 6 to 10 carbon atoms and an “alkyl group” having 1 to 8 carbon atoms. Examples include, but are not limited to, benzyl, phenethylenole, (2-naphthyl) -methyl, 3-phenylpropyl, 4-phenenolevbutinole or 5- (1-naphthyl) pentino! ⁇ .
- ⁇ is a group of “ ⁇ ” in combination with a phenyl group and an “alkyl group” having 1 to 4 carbon atoms.
- alkyl group having 1 to 4 carbon atoms. Examples thereof are benzyl, phenethyl, (2-naphthyl) -Methyl, 3-phenylpropyl, or 4-phenylpuccino ⁇ .
- R alkoxy group used in this specification j Represents a branched or cyclic alkoxy group; An alkoxy group having 1 to 8 carbon atoms is preferred. Examples of this include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy or n-heptyloxy. More preferably, it is an alkoxy group having 1 to 6 carbon atoms. Even more preferred is an alkoxy group having 1 to 4 carbon atoms. Examples of this include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxyne, n-butoxy, tert-butoxy.
- halogen represents F, Cl, Br or I. F, C 1 or Br is preferred.
- C 1 such as “C 1” is followed by “C 1” and “C 1 -C 6” represents a range from 1 to 6 carbon atoms.
- the number of carbon atoms is different, it means that group having that number of carbon atoms.
- C 1 -C 6 alkyl group means an alkyl group defined by “C 1 -C 8 alkyl group” having 1 to 6 carbon atoms. The same applies to the treatment of carbon number in other groups.
- substituted silyl group refers to a silyl group that can be used as a protecting group for water.
- Preferred are a trimethinoresilinore group, a tert-butyl dimethinoresilinole group, a tert-butinoresiferinylsilinore group, or a triethinoresilyl group, and more preferably a tert-butyldimethinosilyl group.
- C 9 -C 4 alkoxy group substituted with 9 halogens and one or more substituents selected from the group consisting of —NR 12 R 13 .
- the number of preferred layers is 1 to 3.
- R 12 represents a hydrogen atom, a CI-C 8 alkyl group, a phenyl group, or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R ′ 3 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C1-C 4 alkyl group Represents a group.
- R 12 and R 13 are alkyl groups,: ⁇ may be combined with the nitrogen atom to which they are bonded to form a 5- or 7-membered ring.
- this ring contains 1 to 2 heteroatoms selected from the group consisting of ⁇ atoms, nitrogen atoms, and ⁇ 3 ⁇ 4 [yellow atoms.
- R 5 ° represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a C6-C14 aryl group, preferably a C1-C4 alkyl group or phenyl group It is.
- R 51 represents a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group.
- R 52 and R 53 may be the same or different, and are a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 alkyl group, a C 6 -C 14 aryl group or an aralkyl. Represents a group.
- ⁇ when R 52 and R 53 are an alkyl group may be combined with the nitrogen atom they are forming to form a shed or an unsaturated 5- to 7-membered ring. ,.
- this ring contains 1 to 2 heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and an O3 ⁇ 4S yellow atom. Also good.
- Preferred R 52 and R 53 may be the same or different, and are a hydrogen atom or a C1-C4 alkyl group.
- halogens substituted C 1 - C4 alkoxy group and - one or more of the is selected from the group consisting of NR 44 R 45.
- substituents selected from the group consisting of halogen, C 1 -C 4 anolalkyl group, phenyl group, and amino group are preferable.
- the number of preferred substituents is 1 to 3.
- R 4 4 represents a hydrogen atom, a C 1 -C 8 alkyl group or a benzyl group, preferably a 3 ⁇ 4 ⁇ silicon atom or a CI-C 4 alkynole group.
- R 45 represents a hydrogen atom, a C 1 -C 8 anoalkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group. And preferably a hydrogen atom or a C1-C4 alkyl group.
- R 54 represents a CI-C8 alkyl group, a C3-C8 cycloalkyl group, or a C6-C14 aryl group, preferably a C1-C4 alkyl group or a phenyl group. is there.
- R 55 represents a C1-C8 alkyl group, a C3-C8 alkyl group, or a C6-C14 aryl group, preferably a C1-C4 alkynole group. is there.
- R 56 and R 57 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 anolequinol group, a C 3 -C 8 cycloalkynole group, a C 6 -C 14 aryl group or an aralkyl group.
- a hydrogen atom or a C1-C4 alkyl group Preferably a hydrogen atom or a C1-C4 alkyl group ;
- R 4 6 represents a hydrogen atom, a C 1 -C 8 alkyl group or a benzyl group, preferably a hydrogen atom or C 1 -C 4.
- the Archi Is a group R 47 is a hydrogen atom, C 1 -.
- Anorekiru group C 8 benzyl group, Asechiru group, ter ⁇ - represents a butoxycarbonyl group or a base Nji Ruo alkoxycarbonyl group, preferably a hydrogen atom or a C 1 -An alkyl group of C 4 R 58 represents an alkyl group of CI-C8, a cycloalkyl group of C 3-C 8, or an aryl group of C 6-C 14, preferably C 1 -An alkyl group or a phenyl group of C4 R 59 is a C1-C8
- R 60 and R 61 may be the same or different, and may be a hydrogen atom, a C 1 -C 8 acrylyl group, a C 3 -C 8 alkyl group, a C 6 -C 14 aryl group or an aralkyl group. And preferably a hydrogen atom or an alkyl group of CI-C4.
- R 14 represents a hydrogen atom, a CI-C 8 alkyl group, a phenyl group, or a benzyl group, preferably a hydrogen atom or a CI-C 4 alkyl group.
- the R] 5 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, an acetyl group, a tert-butoxycarbonyl group or a pendinoreoxycarbonyl group, preferably a hydrogen atom or a C 1- C 4 represents an alkyl group.
- R 62 represents a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group. Group or a phenyl group.
- R 63 represents a C 1 -C 8 alkenoquinole group, a C 3 -C 8 alkyl group, or a C 6 -C 14 alkenyl group, preferably a C 1 -C 4 alkyl group. is there.
- R 64 and R 65 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aryl group or an aralkyl group.
- 3 ⁇ 4 ⁇ in which R 64 and R 65 are alkyl groups may be combined with the nitrogen atom to which they are bonded to form a saturated or unsaturated 5- to 7-membered ring.
- this ring contains 1 to 2 heteroatoms selected from the group consisting of ⁇ atom, nitrogen atom, and ⁇ 3 ⁇ 43 ⁇ 4yellow atom Even if you are doing, good.
- Preferred R 64 and R 65 may be the same or different, and are a hydrogen atom or a C1-C4 alkyl group.
- C 1 -C 4 alkyl group, C 1 -C 8 alkoxy group, phenyl group, and one or more ⁇ groups selected from the group consisting of amino groups are preferable.
- the preferred number of positions 3 ⁇ 4 is 1 to 3.
- R 16 represents a hydrogen atom, a C1-C8 alkyl group or a benzyl group, preferably a hydrogen atom or a C1-C4 alkyl group.
- R 17 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C 1 -C4 alkyl group It is.
- R 66 represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a C6-C14 aryl group, and preferably a C1-C4 alkyl group or a phenyl group.
- R 67 represents a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group.
- R 68 and R 69 may be the same or different, and are a hydrogen atom, a C 1 -C 8 anolenoquinol group, a C 3 -C 8 cycloanolenoyl group, a C 6 -C 14 aryl group or an aralkyl group. And preferably a hydrogen atom or a C 1 -C 4 alkynole group.
- R 18 represents a hydrogen atom, a CI-C8 alkyl group or a benzyl group, preferably a hydrogen atom or a C1-C4 alkyl group.
- R 19 represents a hydrogen atom, a C 1 -C 8 ananolyl group, a benzyl group, a acetyl group, a tert -butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group It is a group.
- R 70 represents a C 1 -C 8 alkyl group, a C 3 -C 8 alkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group. Group or a phenyl group.
- R 71 represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a C6-C14 aryl group, preferably a C1-C4 alkynole group.
- R 72 and R 73 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aryl group or an aralkyl group, Preferably, they are a hydrogen atom or a C1-C4 alkyl group.
- R 2 0 is a hydrogen atom, C 1 - alkyl group or a benzyl group C 8, preferably had or hydrogen atom is C1 - an alkyl group having C 4.
- R 21 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, an acetyl group, a tert-butoxycarboninole group or a benzyloxycarbonyl group, preferably a hydrogen atom or C 1 -C 4 It is an alkyl group.
- R 74 represents a CI-C8 alkyl group, a C3-C8 cycloalkyl group, or a C6-C14 aryl group, preferably a C1-C4 alkyl group or phenyl group. is there.
- R 75 represents an alkylene group of C1 to C8, an alkyl group of C3 to C8, or an aryl group of C6 to C14, and preferably an alkyl group of C1 to C4. It is.
- R 76 and R 77 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkenyl group, a C 6 -C 14 aryl group or an aralkyl group, Preferably, they are a hydrogen atom or a C1-C4 alkyl group.
- R 8 an alkyl group of CI-C8, substituted with 1 to 9 halogens, and a C1-C4 alkyl group, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 Cyclic alkyl group, aryl group of C 6 -C 14, heterocyclic group, aralkyl group of C 7 -C 16, alkoxy group of C 1 -C 8,! One or more positions selected from the group consisting of a C 1 -C 4 alkoxy group substituted with ⁇ 9 halogens, and —NR 22 R 23 .
- halogen,-(C 0) ⁇ H CI-C4 alkyl group, C1-C4 alkyl group formed by 19 halogens, phenyl group, C1-C4 One or more units selected from the group consisting of an alkoxy group and an amino group.
- the number of substituents is preferably 13.
- R 22 represents a hydrogen atom, a C 1 -C 8 alkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 23 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group It is a group.
- R 78 represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group Group or a phenyl group.
- R 79 represents a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a C 6 -C 14 aryl group, and preferably a C 1 -C 4 alkyl group.
- R 80 and R 81 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkynole group, a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aryl group or an aralkyl group, preferably Is a hydrogen atom or an alkyl group of CI-C4.
- the group in which the nitrogen atom in the heterocyclic group is substituted is selected from the group consisting of a C1-C4 alkyl group, a benzinole group, a acetyl group, a tert-butoxycarbonyl group, and an benzyloxycarbonyl group.
- R 7 , R 8 , R 9 , and R 10 may be the same or different, hydrogen! ⁇ Child, optionally C 1 -C 8 alkyl group, optionally substituted C 3- It represents a C 8 cycloalkyl group or an optionally substituted C 6 -C 14 aryl group.
- R 9 and R 10 are an alkyl group, together with the nitrogen atom to which they are bonded, they may form a saturated or inert 5- to 7-membered ring. Further, in addition to the nitrogen atom to which they are bonded, this ring may contain 1 to 2 heteroatoms selected from the group force consisting of an oxygen atom, a nitrogen atom, and a yellow atom.
- R 7 , R 8 , R 9 , and R ′ 0 may be the same or different, and are preferably a hydrogen atom or an optionally substituted C 1 -C 4 alkyl group.
- R 26 to R 43 , R 133 , R 15 . , And R 151 may be the same or different, and may be a hydrogen atom, an optionally substituted CI-C 8 anoalkyl group, an optionally substituted C 2 -C8 anolenyl, or an optionally substituted group.
- R 30 and R 31 , R 32 and R 33 , R 37 and R 38 , R 42 and R 43 , and R 15G and R 15 ] are alkyl groups, respectively, Together, they may form saturated or non-Si 5 to 7-membered rings. Further, in addition to the nitrogen atom to which they are bonded, this ring may contain 1 to 2 heteroatoms selected from the group consisting of an atom, a nitrogen atom, and a yellow talcum.
- R 26 to R 43 , R 133 , R 15 °, and R 15 may be the same or different, more preferably a hydrogen atom, an optionally substituted C 1 -C 8 alkyl group, Or a C 3 -C 8 cycloalkyl group or an optionally substituted C 6 -C 14 aryl group. More preferred is a hydrogen atom or an optionally substituted CI-C4 alkyl group.
- X 1 or X 2 represents 0, S, N—CN or NH, preferably O. r represents 0 to 2, and is preferably 0 or 2.
- C1-C4 alkyl group substituted with ⁇ 9 halogens C3-C8 cycloalkyl group, C6-C14 aryl group, C1-C8 alkoxy group, 1-9 halogens
- R 24 represents a hydrogen atom, a C 1 -C 8 alkyl group or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 25 represents a hydrogen atom, a C1-C8 alkynole group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C1-C4 alkyl group. is there.
- R 82 is
- R 83 is a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or. Represents an aryl group of 6-C14, and preferably an alkyl group of CI-C4.
- R 84 and R 85 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkynole group, a C 3 -C 8 cycloanolalkyl ⁇ group, a C 6 -C 14 aryl group or an aralkyl group, preferably It is a hydrogen atom or an CI-C4 anoalkyl group.
- C 1 -C 4 alkyl group C 6 -C 14 aryl group, C 1 -C 8 alkoxy group, C 1 -C4 alkoxy group substituted with 1 to 9 halogens, and one or more substituents selected from the group consisting of 'and -Nl 31 R ] 32 .
- One or more substituents selected from the group consisting of 132 are preferably, a halogen, a cyanoalkyl group of CI-C4, and an alkyl group of CI-C4 substituted with 1 to 9 halogens, one or more substituents selected from the group consisting of is there.
- a preferred number of positions is 1 to 3.
- R 131 represents a hydrogen atom, a C 1 -C 8 alkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 132 is a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, It represents a cetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably an ifck element atom or a C 1 -C4 alkyl group.
- R 127 represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 alkyl group, or a C 6 -C 14 aryl group, preferably a C 1 -C 4 alkyl group or A phenyl group.
- R 128 represents an aralkyl group of CI-C8, a cycloalkyl group of C 3 -C 8, or an aryl group of C 6 -C 14, preferably a C 1 -C 4 alkyl group. .
- R 129 and R 13G may be the same or different, and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 alkyl group, a C 6 -C 14 aryl group or an aralkyl group. And preferably a hydrogen atom or a CI-C4 alkyl group.
- the position of 3 ⁇ 4 ⁇ in which the nitrogen atom in the heterocyclic group is substituted is selected from the group consisting of an alkyl group of CI-C4, a besidyl group, a acetyl group, a tert-butoxycarbonyl group, and a benzyloxycarbonyl group. Is one or more groups. -
- R 1 is preferably hydrogen.
- R 2 is preferably hydrogen.
- R 3 is preferably an optionally substituted CI-C 8 aralkyl group, an optionally substituted C 3 -C 8 cycloalkyl group, or a substituted or unsubstituted, It is a cyclic group.
- the number of substituents is more preferably 1 to 3 in the case of halogen. It is a piece ⁇ Of the substituent other than 1 is 1.
- R 86 represents a C1-C4 alkyl group, a C3-C8 cycloalkyl group, or a phenyl group, and preferably a C1-C4 alkyl group
- R 87 and R 88 may be the same or different and each represents a hydrogen atom, a CI-C8 alkyl group, a C3-C.8 cycloalkyl group, a phenyl group or an aralkyl group, preferably a hydrogen atom or C 1 -C 4 alkyl group
- R 89 represents a hydrogen atom, a C 1 -C 4 alkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 90 represents a hydrogen atom, a C 1 -C 4 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or C1 -.
- an alkyl group of C 4 or, R 89 and R 90 If alkyl groups, together with the nitrogen atom to which they are attached, a saturated or may form a 5-7 membered unsaturated ring.
- R 89 and R 9D force binding
- one or two heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom, and an ⁇ yellow atom may be contained. ).
- R 91 represents a hydrogen atom, a C 1 -C 8 alkyl group, a phenyl group or a benzyl group, and preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 92 represents a hydrogen atom, a CI-C 8 alkyl group, a benzyl group, an acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or CI -Represents an alkyl group of C 4).
- this preferred R 3 which may be substituted, may be an unsubstituted ⁇ heterocyclic group, a substituted bicyclic heterocyclic group, an am «heterocyclic group. Or, it is a substituted bicyclic heterocyclic group, and more preferably a heterocyclic group, a substituted heterocyclic group.
- R 93 represents a hydrogen atom, a C 1 -C 8 alkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group.
- R 94 represents a hydrogen atom, a C 1 -C 8 aralkyl group, a pendyl group, an acetylenol group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom, but still a C 1 -C.4 alkyl group.
- the position of ⁇ & in which the nitrogen atom in the heterocyclic group is substituted includes the group consisting of a C1-C4 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group, and an benzyloxycarbonyl group.
- R 3 is more preferably il ⁇ from N, O and S 1. or an unsubstituted 5- to 8-membered heterocyclic group containing 2 heteroatoms, substituted with 1 amino group A C 1 -C 4 anoalkyl group, or a C 3 -C 8 alkyl group substituted with one amino group.
- R 3 is more preferably a ⁇ 8 containing one N atom, a 58-membered ⁇ saturated heterocyclic group, a C1-C4 alkyl group substituted with one amino group, or one amino group A C 3 -C 8 cycloalkyl group substituted with a group.
- R 3 is even more preferably a piperidyl group, a pyrrolidinyl group or a cyclyl group substituted with one amino group.
- R 3 is even more preferably a piperidyl group or a pyrrolidyl group.
- R 4 is preferably a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C3-C8 cycloalkyl group, an optionally substituted aralkyl group, or a substituted A heterocyclic group which may be substituted, an aryl group of C 6 —C 14 which may be substituted, or a heterocyclic group which may be substituted;
- the optionally substituted C1-C8 alkyl group which is the preferable R 4 include a substituted C1-C8 alkyl group, or a substituted C1-C8 alkynole group.
- R 95 is C1-C8 An alkyl group, a C3-C8 cycloalkyl group, or a phenyl group, preferably a CI-C4 alkyl group or a phenyl group
- R 96 is a C1-C8 alkyl group, C3-C8 A cycloalkyl group or a phenyl group, preferably a C1-C4 alkyl group
- R 97 and R 98 may be the same or different, a hydrogen atom, a C 1 -C 8 alkyl group Represents a C3-C8 cycloalkyl group, a phenyl group or an aralkyl group.
- R 97 and R 98 is an alkyl group:. ⁇ Is connexion such together with the nitrogen atom to which they are attached, a saturated or may form a 5- to 7-membered ring not mouth further the ring May contain one or two heteroatoms selected from the group consisting of oxygen atoms, nitrogen atoms, and ⁇ yellow atoms in addition to the nitrogen atoms to which R97 and R98 are bonded. . Le, preferably R 97 and R 98 are the same or different connexion is good, a hydrogen atom or a C1 - is an alkyl group of C 4 ..
- R 99 is a hydrogen atom, C1 - alkyl C 4, phenyl group or Represents a benzyl group, preferably a hydrogen atom or a C 1 -C 4 alkyl group
- R 100 represents a hydrogen atom, a C 1 -C 4 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a base;
- the number of substituents is preferably 1 to 3 for halogen, and 1 for other substituents, where R 105 is a hydrogen atom, C 1 -Represents an alkyl group of C 8, a phenyl group or a benzyl group, preferably a hydrogen atom or an alkyl group of CI-C 4 R 106 is a hydrogen atom, C 1-.
- R 101 representing the C4 alkyl group is C1 - C8 alkyl group
- R 102 represents an alkyl group of C1-C8, a cycloalkyl group of C3-C8, Or a phenyl group, preferably a C 1 -C4 alkyl group
- R 103 and R 104 may be the same or different, a hydrogen atom, a CI-C 8 alkyl group, a C3-C8 Represents a cycloalkyl group, a phenyl group, or a
- the optionally substituted aralkyl group which is the preferable R 4 include a aralkyl group in which the aralkyl group is a combination of an unsubstituted C 1 _C 4 alkyl group and an unsubstituted phenyl group, or An aralkyl group comprising a combination of a substituted C 1 -C 4 alkyl group and a substituted phenyl group can be mentioned.
- R 111 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or C 1- C4 alkyl group.
- R 112 represents a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, or a phenyl group, preferably CI-C 4 An alkyl group or a phenyl group;
- R ,. 7 represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a phenyl group, and preferably a CI-C4 alkyl group.
- R 108 represents a C1-C8 alkyl group, a C3-C8 cycloalkyl group, or a phenyl group, and is preferably a CI-C4 alkyl group.
- R 109 and R 110 may be the same or different and each represents a hydrogen atom, a C 1 -C 8 alkyl group, a C 3 -C 8 cycloalkyl group, a phenol group or a benzyl group, preferably a hydrogen atom Or a C1-C4 alkyl group.
- R 4 which may be substituted, may be a heterocyclic alkyl group represented by M or a heterocyclic alkyl group which is substituted, and more preferably A combination of a substituted C 1-C4 alkyl group and a substituted aromatic ring group ⁇ : or an unsubstituted C 1 -C 4 alkyl group and a difficult aromatic silicon group And more preferably a heterocyclic alkyl group comprising a combination of a monocyclic or bicyclic aromatic heterocyclic group substituted with an unsubstituted C1-C4 alkyl group, or an S-substituted A C 1 -C 4 alkyl group of the above or a combination of a bicyclic aromatic ring group and a heterocyclic alkyl group.
- a heterocyclic alkyl group converted here, a ⁇ -converted C 1—C 4 alkyl group and a monocyclic group consisting of a monocyclic group, or a A heterocyclic alkyl group consisting of a 3 ⁇ 41 or bicyclic aromatic ring group substituted with a C 1 -C 4 alkyl group ⁇ : on the carbon atom is a halogen,-(C O) OH C 1 -C 4 Anolequil, Selected from the group consisting of a C ⁇ -C4 anoalkyl group substituted with 9 halogens, a C 1 -C4 anorecoxy group, and a C 1 -C4 alkoxy group substituted with 19 halogens One or more groups.
- the alkino portion of the complex ⁇ alkyl group is substituted, and the ⁇ group on the carbon atom of the heterocyclic ring is replaced with a rogen, an alkyl group of CI-C4, and 19 halogens.
- the substituent in which the nitrogen atom in the heterocyclic group is formed is selected from the group consisting of C1-C4 alkyl group, benzyl 3 ⁇ 4, acetyl group, tert-butoxycarbonyl group, and benzyloxycarbonyl group.
- One or more groups More preferably, it is a C 1 -C 4 alkynole group, or a tert-butoxy carbonyl reno group.
- the optionally substituted C 6—C 14 aryl group which is the preferable R 4 include, but are not limited to, an unsubstituted C 6—C 10 aryl group, or a substituted C 6—C 10 And more preferably an E-substituted phenolino group or a substituted phenolino group.
- the substituted C 6— C 10 aryl group or the substituted phenyl group may be halogen, —CN—N 0 2 , or optionally substituted C 1 -C 8 alkyl.
- W is a hydrogen atom, an optionally substituted CI-C8 anoalkyl group, an optionally substituted C 2 -C 8 anorekeninole, an optionally substituted C 2 -C 8 anorequinolole, or an optionally substituted
- W is preferably a hydrogen atom, an optionally substituted CI-C4 anolenoquinole group, an optionally substituted C3-C8 cycloalkyl group, or optionally substituted.
- R 113 to R 121 which may be the same or different, are a hydrogen atom, an optionally substituted C 1 -C 8 alkyl group, an optionally substituted C 2 -C 8 alkenyl, C2-C 8 alkynyl, optionally substituted C 3-C 8 cycloalkyl group, optionally substituted C 6-C14 aryl group, optionally substituted A group, an optionally substituted aralkyl group or an optionally substituted aryl ring alkyl group; Or R] 16 and 13 ⁇ 4 117 , R " 8 and R 119 and R 12, and R 121 are alkyl groups, together with the nitrogen atom to which they are bonded, saturated or unsaturated In addition to the nitrogen atom to which they are bonded, this ring is selected from the group consisting of an oxygen atom, a nitrogen atom, and a t3 ⁇ 4 yellow atom.
- R] 13 to R 12 1 may be the same or different, preferably a hydrogen atom, may be substituted C1-C 8 represents an optionally substituted C 3 -C 8 cycloalkyl group or an optionally substituted C 6 -C 14 aryl group; R 113 to R 12 are the same or different. R 113 is more preferably a hydrogen atom or an optionally substituted C 1 -C 4 alkyl group.
- R 12] may be the same or different, and more preferably a hydrogen atom or C 1 -C 4 anoalkyl.
- heterocyclic group which may be substituted which are preferable R 4 , include an unsubstituted monocyclic heterocyclic group, the following bicyclic heterocyclic group, a substituted heterocyclic group or a substituted group.
- a bicyclic heterocyclic group More preferably, it is a substituted bicyclic aromatic ring group or a substituted bicyclic aromatic ring group. Where 3 ⁇ 4 ⁇ is a heterocyclic group, a substituted bicyclic heterocyclic group or a substituted bicyclic aromatic ring group is A halogen, -CN, -N0 2s C1-C8 alkyl group,:!
- R 123 represents a hydrogen atom, a C1-C8 alkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or a CI-C4 aralkyl group.
- R 124 represents a hydrogen atom, a C 1 -C 8 alkyl group, a benzyl group, a acetyl group, a tert-butoxycarbonyl group or a benzyloxycarbonyl group, preferably a hydrogen atom or a C 1 -C 4 It is an alkyl group.
- R 122 represents a CI—C 8 alkyl group, a C 3 -C 8 cycloanolalkyl group, or a phenyl group, and is preferably a CI—C 4 alkyl group.
- R 125 and R 126 which may be the same or different, each represents a hydrogen atom, a C 1 -C 8 alkenyl group, a C 3 -C 8 cycloalkyl group, a phenyl group or a benzyl group, preferably a hydrogen atom or C 1 -C4 alkyl group.
- the substituent of ⁇ is a group consisting of an aralkyl group of CI-C4, a benzyl group, an acetyl group, a tert-butoxycarbonyl group, and an benzyloxycarbonyl group One or more groups selected from More preferably, it is a C1-C4 alkyl group or a tert-butoxycarbonino group.
- R 4 is more preferably a substituted phenyl group, a phenyl group substituted with one —0— (CH 2 ) m —W, an unsubstituted bicyclic aromatic ring group, a C1-C4 A bicyclic aromatic ⁇ -ring group substituted with an alkyl group, or a bicyclic aromatic male ring group substituted with a C 1 -C 4 alkyl group substituted with 1 to 9 halogen atoms.
- a bicyclic aromatic ring group is a phenyl group.
- R 4 is a substituted phenyl group, a phenyl group substituted with one —0— (CH 2 ) m —W, a substituted: ⁇ 1 ⁇ difficult group, one C 1— C4 A bicyclic aromatic heterocyclic group substituted with an alkyl group, or a bicyclic aromatic group substituted with one (CI-C4 alkyl group substituted with 1 to 9 halogens); Heterocyclic group (here CI-C 4 alkyl group
- Bicyclic aromatic heterocyclic groups include 5-benzothiazolyl, 6-benzothiazolyl, 5-benzoxazolyl, 6-benzoxazolyl, 5-benzozoenyl, 6-benzothenyl, 5-benzofuranyl, and 6-benzofuranyl.
- n is preferably. It is.
- R 6 is preferably a methyl group.
- X 1 or X 2 is preferably o. '
- r is preferably 0 or 2.
- Z] to Z 4 are preferably a hydrogen atom.
- - CN substituted have good C 1 - C8 of Anorekinore group or - O - is W - (CH 2) m.
- Represents a C1-C8 alkoxy group, where m 2-4. ⁇ ; N is an 0; -A- B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3 -C 8 A cycloalkyl group or a substituted or non-substituted rhenic ring group;: 4 is a substituted or non-substituted rhenic ring group;
- n is 0;-A-B-is-CH 2 -.CH 2- .
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C 1 -C 8 aralkyl group, optionally substituted C 3 -C 8 A cycloalkyl group, or a substituted or unsubstituted good heterocyclic group;
- R 4 is an optionally substituted phenyl group;
- the substituent of the phenyl group which may be substituted is halogen, —CN, an optionally substituted C 1 -C 8 anolenoquinole group or —O— (CH 2 ) m —W.
- Represents an alkoxy group of CI-C8, which may be m 2-4. ⁇ ; N is an 0; - A - B - is - CH 2 - CH 2 - CH 2 - or - CH 2 - CH 2 - CH 2 - CH 2 - is.
- R 1 is hydrogen; R 2 ffcK element; R 3 is an optionally substituted C1-C8 alkyl group, optionally substituted C3-C8 cyclo An alkyl group, or a substituted or unsubstituted aryl group; R 4 is an optionally substituted aryl group; n is 0
- R fcK element; R 2 ifcK element; R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3 -C 8 Or an optionally substituted phenyl ring ⁇
- R 4 is an optionally substituted phenyl group (wherein the optionally substituted phenyl group is a halogen , -CN, may be substituted R 1 -C8 anolenoquinole group or -O-(CH 2 ) m -W.
- Ri is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3 -C 8 A cycloalkyl group, or an optionally substituted heterocyclic group;
- R 4 is an optionally substituted cycloalkyl group;
- n is 0;
- R 1 is hydrogen; R 2 ii7K element; R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3 -C 8 A cycloalkyl group, or an optionally substituted heterocyclic group; R 4 is a hydrogen atom, an optionally substituted CI -C8 anoalkyl group, an optionally substituted C 3-C 8 N is ⁇ ;-A- B
- - is - CH 2 - CH. -That's it.
- R'ifck element In formula (1), R'ifck element; R 2 is hydrogen; R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3-C 8 is a cycloalkyl group that may be substituted, or a good carbocyclic group; R 4 is a hydrogen atom, an optionally substituted CI-C8 anoalkyl group, or an optionally substituted C 3- cycloalkyl group C 8; n is an 0; - a - B - is - CH 2 - CH 2 - CH 2 - or - CH 2 - CH 2 - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C 1 -C 8 alkyl group, optionally substituted C 3 -C A cycloalkyl group of 8 or a substituted or unsubstituted ring group;
- R 4 is a hydrogen atom, an optionally substituted CI-C8 Norequinole group, optionally substituted C 3 -C 8 cycloalkyl group;
- n is 0;
- R'lfc element In formula (1), R'lfc element; R 2 is hydrogen; R 3 is an optionally substituted C3-C8 cycloalkyl group; R 4 is substituted
- the phenyl group which may be substituted with the phenyl group which may be substituted is a halogen, or a C 1 -C 4 alkyl group which may be substituted.
- N is an 0; - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C3-C8 cycloalkyl group;
- R 4 is substituted
- the phenyl group which may be substituted ⁇ the ⁇ group of the phenyl group which may be substituted here is -0- (CH 2 ) m -W.
- N is an 0;
- - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted C 3 -C 8 cycloalkyl group;
- R 4 is substituted Even if it is good, it is an aromatic ⁇ -membered ring group;
- ⁇ is 0;
- -A- ⁇ - is -CH 2 -CH 2- .
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted saturated heterocyclic group;
- R 4 is an optionally substituted phenyl.
- substituent of the phenyl group which may be substituted with a group include a halogen, and an optionally substituted CI-C4 anoalkylene group.
- N is an 0;
- - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 may be substituted and R may be a saturated heterocyclic group;
- R 4 may be substituted Good phenyl group ⁇
- the substituent of the phenyl group which may be substituted here is -0- (CH 2 ) m -W.
- Represents a group, where m 2-4. ⁇ ; N is an 0; - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an optionally substituted saturated heterocyclic group;
- R 4 is an optionally substituted aromatic group. It is 3 ⁇ 4 «heterocyclic group; n is than zero der; - a - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen; R 2 is halogen; R 3 is an optionally substituted saturated heterocyclic group; R 4 is an optionally substituted phenyl Examples of the phenylol group which may be substituted here are halogen, and an optionally substituted CI-C4 alkyl group.
- N is an 0; - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen; R 2 is halogen; R 3 is a saturated heterocyclic group which may be substituted; R 4 is a phenyl group which may be substituted; As a difficult group of the phenyl group which may be transferred with a saw is -0- (CH 2 ) m -W.
- N is an 0; - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen; R 2 is halogen; R 3 is an optionally substituted saturated heterocyclic group; R 4 is optionally substituted. , be aromatic female heterocyclic group; n is 0; -A- B - is - CH 2 "CH 2 - is.
- R 1 is hydrogen; R 2 3 ⁇ 4 TK; R 3 is an optionally substituted piperidyl group or pyrrolidyl group; R 4 is optionally substituted
- the phenyl group may be substituted with a phenyl group, and the phenyl group is converted to —O— (CH 2 ) m —W.
- n is 0; -A-B- is -CH 2 CH 2- .
- R'ifcR element is hydrogen
- R 3 is an optionally substituted piperidyl group or pyrrolidyl group
- R 4 is optionally substituted it is Fang 3 ⁇ 43 ⁇ 43 ⁇ 4 heterocyclic group
- n is 0
- - a - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is an unsubstituted piperidyl group or pyrrolidyl group;
- R 4 is an optionally substituted phenyl group
- the substituent of the phenyl group which may be substituted at this is -0- (CH 2 ) m -W.
- m 2 to 4.
- n is 0;
- - A - B - is - CH 2 - CH 2 - is.
- R 1 is hydrogen;
- R 2 is hydrogen;
- R 3 is cyclohexyl substituted with an amino group;
- R 4 is an optionally substituted phenyl group ⁇
- the position of the phenyl group which may be substituted is -0- (CH 2 ) m -W.
- N is an 0;
- - A - B - is - CH 2 - CH 2 - is.
- R'ifck element In the formula (1), R'ifck element; R 2 is hydrogen; R 3 is a cyclohexyleno group substituted with an amino group; R 4 is a substituted or unsubstituted group. it is Fang group; n is 0; - A- B - is - CH 2 - CH 2 - is.
- groups ⁇ are represented by 1 to! ⁇ 4 , n, and-in formula (1).
- the above 1) to 23 may be mentioned.
- the compound of the present invention has an acid its in its molecule. This: ⁇ can be converted to a medically acceptable salt if necessary.
- Such salts include the non-toxic power thio ⁇ , specifically, alkali metal ions such as Na + and K +, alkalis such as Mg 2+ and Ca 2+ : metal ions, Al 3+ , Zn 2+ and other ions, or ammonia, tritinoleamine, ethylenediamine, propanediamine, pyrrolidine, piperidine, piperazine, pyridine, lysine (Ly si ne), choline, ethanolamine, ⁇ , ⁇ -dimethylolethan Salts with m ⁇ s such as Noreamine, 4-Hydroxypiperidine, Darcosamine, ⁇ -Methinoregnole Power Min.
- alkali metal ions such as Na + and K +
- alkalis such as Mg 2+ and Ca 2+
- metal ions Al 3+ , Zn 2+ and other ions
- ammonia tritinoleamine
- ethylenediamine propanediamine
- the compounds according to the present invention include enantiomers, including racemates and phototropes.
- the age at which two or more asymmetric carbons are subjected to the compound according to the present invention includes both diastereoisomers.
- the compound according to the present invention has a trans-cis-accepting isomer, a trans-isomer or a cis-isomer is included.
- Examples of the compound represented by the formula (1) of the present invention include compounds represented in the following Tables A to G.
- the pyrazo-mouth pyrimidium conductor represented by the above formula (l) is, for example, tautomerized by the T-form.
- Examples of the compound represented by the formula (2) of the present invention include compounds corresponding to RR 2 R 3 R n and —A—B— described in Table AG above.
- the compound of the present invention can be synthesized by the following method. In each formula, R ] to
- R-A- B-and n are as defined in formula (1).
- Ett in the chemical formulas as a condition or solvent are only examples as shown in the text.
- the symbols in the text and the table, and the abbreviations of the solvents represent the following, respectively.
- TBS tert-Ptyldimethinoresilinore
- HAT.U O-(7-azabenzoto riazoinore-1 -inore)-N, N, N ', N'-Teto Rametino Leronium Hexafnoreo mouth phosphate
- the compound represented by the formula) is obtained by subjecting the compound represented by the formula) to a suitable temperature (for example, ethanol or methanol) from room temperature under flowing conditions, such as sodium ethoxide or sodium methoxide. And allylmalonic acid diester Can be obtained. (Reference:]. Me d. Ch em., 1 976, 19, 296. and]. Me d. C he m., 1977, 20, 296.)
- the compound represented by the formula () can be obtained by subjecting the compound represented by the formula () to a suitable (eg It can be obtained by using a halogenating agent (for example, oxyphosphorus) under mechanical or ⁇ ft.
- a suitable eg It can be obtained by using a halogenating agent (for example, oxyphosphorus) under mechanical or ⁇ ft.
- the compound represented by the formula () or (15) can be obtained by mixing the compound represented by the formula (5.) or in an appropriate solvent (for example, THF-water mixed Fujinaka) in the range of 0 ° C to room temperature. It can be obtained by oxidation conditions (for example, sodium periodate and osmium tetroxide).
- an appropriate solvent for example, THF-water mixed Fujinaka
- oxidation conditions for example, sodium periodate and osmium tetroxide
- the chemical formula represented by the formula () or (16) is obtained by converting the compound represented by the formula (6.) or ( ⁇ 5), respectively, from 0 ⁇ to .40 ° in an appropriate shelf (eg ethanol or methanol). It can be obtained by TO with a reducing agent (for example, sodium hydrogen hydride) in the range of 3 to 5 of C.
- a reducing agent for example, sodium hydrogen hydride
- the compound represented by the formula () or ( ⁇ _8) is obtained by converting the compound represented by the formula (5.) or (1) from 0 ° C to room temperature in an appropriate solvent (eg THF). So, Bora ⁇ (For example, it can be obtained by allowing oxygenated water to flow in borane-dimethylenosulfide and then sodium hydroxide water.
- the compound represented by the formula (7), (J9) or () can be converted into a suitable fine solvent (for example, a compound represented by the formula (9), (1_6), ⁇ ⁇ ) or (i_), respectively.
- a suitable fine solvent for example, a compound represented by the formula (9), (1_6), ⁇ ⁇ ) or (i_), respectively.
- Methylene chloride or DMF in the range of 3 ⁇ 4
- the compound represented by formula. (1 1) or ( ⁇ ) can be prepared by converting the compound represented by formula (10) or () to an appropriate shelf (for example, 2-propanol, DMF, THF or DMF).
- an appropriate shelf for example, 2-propanol, DMF, THF or DMF.
- the compound represented by AJJ is a compound represented by the formula (JL ⁇ ) in an appropriate atmosphere (for example, acetone-water mixed tank) in the range of 0 ° C to room temperature. Osmium oxide and N-methylmorpholine N-oxide). (Reference: Te tra he dr on Let 973 (1976) and Or g.
- the compound represented by the formula () or (14) is obtained by heating the compound represented by the formula ( ⁇ 1) or (13) in a suitable solvent (for example, 1,4-dioxane) from room temperature to the refluxing condition.
- a suitable solvent for example, 1,4-dioxane
- 3 ⁇ 4E can be obtained by reacting with di-tert-butylene dicarbonate.
- the compound represented by the formula is prepared by converting the compound represented by the formula (J_ ⁇ _) in an appropriate shelf solvent (for example, methylene chloride) from Q ° C to room temperature, with an oxidizing agent [for example, Dess-Martin Periodinane, ie 1, 1, 1-tris (acetoxy)-1, 1-dihydric mouth-1, 2-benzodoxo-3 (1H) -on].
- an oxidizing agent for example, Dess-Martin Periodinane, ie 1, 1, 1-tris (acetoxy)-1, 1-dihydric mouth-1, 2-benzodoxo-3 (1H) -on.
- Formula (20), (32) or (U_) can be converted to a compound represented by formula (12), (1 or (4_ ⁇ ), respectively. It can be obtained by using an amine compound represented by the formula R 3- (CH 2 ) n -NH 2 under medium or medium conditions from room temperature to a calothermal flow condition. The age at which R 3- (CH 2 ) n -NH 2 contains an unprotected primary amine in R 3 is represented by the formula (L 2), (14) or (42), respectively. And the compound R.
- the compound represented by the formula (2 1) is prepared by converting the compound represented by the formula (_2_) into a fluoride solvent (for example, tetra n -Petit Ruammonium fluoride) and can be obtained by TO (Reference book: P rotective G roups 1 n Organ 1 c syn nthesis, 3 J ohn Wiley & Sons Inc.)
- a fluoride solvent for example, tetra n -Petit Ruammonium fluoride
- the compounds represented by the formulas (46) and (A3.) can be converted into the appropriate organic difficulty (for example, methylene chloride) in the range from o ° c to room temperature.
- the appropriate organic difficulty for example, methylene chloride
- it can be obtained by using a mesylating agent (for example, methanesulfonyl chloride) under triethylamine).
- the compound represented by the formula is prepared by converting the compound represented by the formula into a suitable shelf solvent (for example, DMF) in the range of 0 ° C to '40 ° C and a peptide condensing agent [for example, 0- (7-aza Benzotriazonole-1 -Innole) -N, N, N ', N' -Tetramethinoleuronic Hexafluorophosphate] and; ⁇ 3 ⁇ 4 (eg diisopropylethinoreamine) 4
- a suitable shelf solvent for example, DMF
- a peptide condensing agent for example, 0- (7-aza Benzotriazonole-1 -Innole) -N, N, N ', N' -Tetramethinoleuronic Hexafluorophosphate
- ⁇ 3 ⁇ 4 eg diisopropylethinoreamine
- the compound represented by the formula (J_Q_) is obtained by converting the compound represented by the formula ( ⁇ J_) from 0 ° to 60 ° in an appropriate 3 ⁇ 4 «medium (eg, DMF, THF or DMF-THF mixture). In a range,
- the compound represented by the formula is prepared by heating the compound represented by the formula in an appropriate supplement (for example, methanol, ethanol) from ot: under the conditions of a reducing agent (for example, cyanohydrogen-boron sodium). Below, it can be obtained by using hydroxylamine.
- an appropriate supplement for example, methanol, ethanol
- a reducing agent for example, cyanohydrogen-boron sodium
- methylene chloride can be obtained by performing w m (for example anhydrous anhydrous) under ta (for example trietinoreamin) at taa of o ° c to 4 ° C.
- w m for example anhydrous anhydrous
- ta for example trietinoreamin
- the compound represented by the formula ( ⁇ _) can be converted to a compound represented by the formula ( ⁇ _) ⁇ ! From 0 ° C to 70 ° in an appropriate shelf (eg DMF, THF or DMF-THF ⁇ ). In the range of C, it can be obtained by using a allyS (eg, allylpromide) under 3 ⁇ 4S (eg, sodium hydride).
- an appropriate shelf eg DMF, THF or DMF-THF ⁇ .
- the compound represented by the formula (3 ⁇ ) is obtained by converting the compound represented by the formula into an olefin metathesis angle [for example, the Gr ubbs angle in the range of 0 ° C to 40 ° C in an appropriate difficulty (for example, toluene). Butterfly or benzylidenebis (trixic hexylphosphine). (Reference: Ang ew. Chem. Int. Ed., 2002, 41, 176.)
- a compound represented by the formula ( ⁇ ) is obtained by reacting a compound represented by the formula (JJL) with a palladium catalyst (for example, methanol, ethanol, 1,4-dioxane-ethanol mixture) at room temperature.
- a palladium catalyst for example, methanol, ethanol, 1,4-dioxane-ethanol mixture
- (Palladium-carbon) can be obtained by coating with hydrogen.
- Each compound represented by the formula is obtained by oxidizing the compound represented by the formula (32) in an appropriate solvent (for example, THF-water mixed solution ⁇ ) in the range of 0 ° C to 40 ° (Sodium oxalate and osmium tetroxide).
- an appropriate solvent for example, THF-water mixed solution ⁇
- ⁇ Sodium oxalate and osmium tetroxide
- a compound represented by formula (52) or is suitable for a compound represented by formula (i) e.g., DMF, methylene chloride, or THF
- a compound represented by formula (i) e.g., DMF, methylene chloride, or THF
- Electrophilic halogenating agents such as 1-chloromethyl-4-fluoro-1,4-diazodiabicyclo [2.2.2] octane bis (tetrafluoroborate), N-bromosuccinimide, or N-chloro Succinimide) and ®S.
- the compound represented by the formula ( ⁇ ) is obtained by combining the compound represented by the formula) with an acid (for example, trifluoroacetic acid) and ⁇ in a suitable cosolvent (eg methylene chloride) in the range of 0 ° C to room temperature.
- a suitable cosolvent eg methylene chloride
- the compound represented by the formula (45) or (48) is obtained by converting the compound represented by the formula (44) or (_i 7), respectively, in an appropriate tank (for example, methylene chloride) from 0 ° C to room temperature. And an acid (for example, trifluoroacetic acid).
- a preparation containing the compound of the present invention or a medically acceptable salt as a component is prepared using a carrier formulation used for generalization and other additives.
- the carrier of transversion may be solid or liquid level, for example, magnesium stearate, starch, tanolec, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, cocoa butter, Examples include ethylene glycono and other commonly used ones.
- MAPKAP-K2P and the present invention are useful include neurodegeneration and / or neurological disorders (including sigmoid disease), losing females, self-compulsive disorders, osteoclast disorders, inflammatory crane diseases , Sputum, diabetes, cancer, J jfc report disorder, angiogenic disorder, cachexia, lunar E3 ⁇ 4, angiogenesis, asthma, or chronic obstructive city disease (COPD)).
- neurodegeneration and / or neurological disorders including sigmoid disease
- lose females self-compulsive disorders, osteoclast disorders, inflammatory crane diseases , Sputum, diabetes, cancer, J jfc report disorder, angiogenic disorder, cachexia, lunar E3 ⁇ 4, angiogenesis, asthma, or chronic obstructive city disease (COPD)
- COPD chronic obstructive city disease
- autoimmune diseases include rheumatoid arthritis, ankylositis, group rheumatoid arthritis, dry arthritis, transfer to host disease, diabetes or Crohn's disease. It is done.
- the dose of the compound of the present invention is usually 1 to 500 mgZ per adult, although it varies depending on disease habits, administration route, patient size and disease SIJ, and disease severity.
- the chemical compounds given to the compounds are corresponding to the compound numbers given to the compounds listed as examples of suitable examples in B3 ⁇ 4A to G above.
- the structure of the new compound tested was mass spectrometry using single quadruple (sigle-quad rupo leinstr ume ntation) equipped with '-NMR and Z or electron spray sources, and its t! Li It was based on a simple analysis method.
- H PLC H time means the compound's heel time (rise: minute) in the H PLC analysis under the following analysis conditions.
- Solvent B 10% ⁇ A: 90% 1 to 13 minutes, ⁇ B: 0% ⁇ 7 '0% Dragon A: 90% ⁇ 30%
- 6-aryl 5, 7-dichloropyrazo mouth [1, 5-a] pyrimidine (1, 82 g, 7. 89 mmo 1) in tetrahydrofuran (24 mL)-water (6 mL) ⁇ (5.12 g, 23.9 mmo 1) and osmium tetroxide (2.5 w / v% tert-butanol, 3 mL, 0.23 mmo 1) were added under ice cooling. ⁇ After the mixture was stirred at room temperature for 3 hours, sodium hydroxide solution was added. The mixture was extracted with ethyl acetate, and the organic substance was extracted with sodium carbonate water and then saturated with fc ⁇ z, and then outlined with sodium.
- the ethyl acetate layer was washed with, and dried with sodium sulfate. After removing sodium sulfate by filtration, the solvent was distilled off. The residue was smoked by column chromatography (25-50% ethynole acetate-hexane) to obtain a coconut compound (3.4 g, 31% yield).
- Example 16 Acetic acid 8-(4-ethoxyphenylamino)-6, 7 -dihydro-1, 4, 5, 8 a -tetraaza- s -yndacene-5 -yl ester (Compound No .: A- 021)
- Example 20 (S)-(4-ethoxifuco: nyl)-(3-fluoro-5-pipedidine-3-inole-6,7-dihydro-mouth-5H-1, 4, 5, 8 a- Synthesis of tetraaza-s-indacene-8-yl) -amine (compound number: A-018) and (S)-(2,3-difluoro-5-pi) Lysine-3 -yl-6, 7 -dihydro-5H- 1, 4, 5, 8 a -tetraaza- s -indacene-8 -yl)-(4-ethoxyphenenole) -amine (compound number) : A-019)
- HPLC soak time (HPLC condition A): 16. 69 minutes.
- the ethyl acetate layer was saturated with water and then with a saturated diet: ⁇ * and then finely woven with sodium tritium.
- the solvent was removed after filtration of Fuji Natomu, and the residue was purified by column chromatography (30% engineered hexane-hexane) to give the title compound (16.8 mg).
- HPLC soak time (HPLC condition A): 10. 04 minutes
- HPLC soak time (HPLC condition A): 5. 40 minutes
- the ethyl acetate layer was made 1 ⁇ with water and then with a saturated diet, and then dried over sodium sulfate. After removing sodium sulfate by filtration, the solvent was distilled off, and the residue was purified by column chromatography (30% ethyl acetate-hexane) to obtain the title compound (1 18.9 mg).
- HPLC soak time (HPLC condition A): 16. 68 minutes
- the compounds listed in Table H below were synthesized using the corresponding starting materials and according to the respective methods described in Examples 11 to 21 and 24 to 26.
- the compound numbers assigned to the compounds in Table H correspond to the compound numbers listed as specific examples in Tables A to G above.
- the structure of the newly-developed ⁇ is: Mass spectrometry using a single quadruple (sigle le qua drupo lei ns t rumentation) with H-NMR and Z or an electron spray source. According to
- HPLC time J indicates the retention time (unit: minutes) of the compound in the H PLC analysis performed under the conditions of the above H PLC Article A or B.
- HPLC conditions means the H at that time Indicates the PLC analysis conditions.
- the compound was dissolved in DMSO to a concentration of 2 Omm o 1 ZL and stored at -20 ° C.
- the preserved cells were sequentially added with DMSO to prepare a 200-fold concentrated solution in the required range. Further, this was adjusted to 1:20 with water to prepare a 10-fold dark blue night of the required range, and 5 iL of each tank was used for every 50 // L of TO.
- the substrate peptide is Lys-Lys-Leu-Asn-Arg-Thr-Leu-Ser-Va1-A1a.
- the compound of the present invention is useful as MAPKAP-K2PJ_3 ⁇ 43 ⁇ 4U. '
- novel MAPKAP-K2P and »3 ⁇ 4, or novel neurodegeneration and / or neurological disorder and dementia inflammatory disease, sepsis, autoimmunity Treatment of sexually transmitted diseases, ruptured I ⁇ live bone disorders, diabetes, cancer, ischemia-reperfusion injury, angiogenic disorders, cachexia, lunar symptom, angiogenesis, asthma, or chronic closure disease (COPD) ⁇ IJ or treatment methods are ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0608722A BRPI0608722A2 (pt) | 2005-03-17 | 2006-03-17 | derivado de pirazolpirimidina ou sal medicinalmente aceitável do mesmo, composição farmacêutica, inibidor de mapkap-k2, e, agente terapêutico |
JP2007508262A JPWO2006098519A1 (ja) | 2005-03-17 | 2006-03-17 | ピラゾロピリミジン誘導体またはその医学上許容される塩 |
EP06729844A EP1864986A4 (en) | 2005-03-17 | 2006-03-17 | PYRAZOLPYRIMIDINE DERIVATIVE OR PHARMACEUTICALALLY SALT OF IT |
AU2006223818A AU2006223818A1 (en) | 2005-03-17 | 2006-03-17 | Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof |
CA002601717A CA2601717A1 (en) | 2005-03-17 | 2006-03-17 | Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005077509 | 2005-03-17 | ||
JP2005-077509 | 2005-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006098519A1 true WO2006098519A1 (ja) | 2006-09-21 |
Family
ID=36991855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/305896 WO2006098519A1 (ja) | 2005-03-17 | 2006-03-17 | ピラゾロピリミジン誘導体またはその医学上許容される塩 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1864986A4 (ja) |
JP (1) | JPWO2006098519A1 (ja) |
KR (1) | KR20070116113A (ja) |
CN (1) | CN101142219A (ja) |
AU (1) | AU2006223818A1 (ja) |
BR (1) | BRPI0608722A2 (ja) |
CA (1) | CA2601717A1 (ja) |
TW (1) | TW200716629A (ja) |
WO (1) | WO2006098519A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
US8389527B2 (en) | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
US20130281474A1 (en) * | 2010-09-28 | 2013-10-24 | Merck Sharp & Dohme Corp. | Fused tricyclic inhibitors of mammalian target of rapamycin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058762A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
WO2004076458A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
WO2004081013A1 (en) * | 2003-03-11 | 2004-09-23 | Teijin Pharma Limited | Protein kinase inhibitors |
WO2005009370A2 (en) * | 2003-07-23 | 2005-02-03 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
-
2006
- 2006-03-17 JP JP2007508262A patent/JPWO2006098519A1/ja active Pending
- 2006-03-17 WO PCT/JP2006/305896 patent/WO2006098519A1/ja active Application Filing
- 2006-03-17 CA CA002601717A patent/CA2601717A1/en not_active Abandoned
- 2006-03-17 BR BRPI0608722A patent/BRPI0608722A2/pt not_active IP Right Cessation
- 2006-03-17 TW TW095109195A patent/TW200716629A/zh unknown
- 2006-03-17 EP EP06729844A patent/EP1864986A4/en not_active Withdrawn
- 2006-03-17 CN CNA2006800085272A patent/CN101142219A/zh active Pending
- 2006-03-17 KR KR1020077023817A patent/KR20070116113A/ko not_active Application Discontinuation
- 2006-03-17 AU AU2006223818A patent/AU2006223818A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058762A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
WO2004076458A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
WO2004081013A1 (en) * | 2003-03-11 | 2004-09-23 | Teijin Pharma Limited | Protein kinase inhibitors |
WO2005009370A2 (en) * | 2003-07-23 | 2005-02-03 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1864986A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
US8389527B2 (en) | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
US20130281474A1 (en) * | 2010-09-28 | 2013-10-24 | Merck Sharp & Dohme Corp. | Fused tricyclic inhibitors of mammalian target of rapamycin |
US8927562B2 (en) * | 2010-09-28 | 2015-01-06 | Merck Sharp & Dohme Corp. | Fused tricyclic inhibitors of mammalian target of rapamycin |
Also Published As
Publication number | Publication date |
---|---|
AU2006223818A1 (en) | 2006-09-21 |
JPWO2006098519A1 (ja) | 2008-08-28 |
EP1864986A4 (en) | 2009-09-16 |
BRPI0608722A2 (pt) | 2016-11-08 |
EP1864986A1 (en) | 2007-12-12 |
KR20070116113A (ko) | 2007-12-06 |
CN101142219A (zh) | 2008-03-12 |
TW200716629A (en) | 2007-05-01 |
CA2601717A1 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3378859B1 (en) | Benzofuran derivative, preparation method thereof and use thereof in medicine | |
TWI765908B (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
EP3345903B1 (en) | Tetracyclic compounds | |
KR101701663B1 (ko) | 3-치환된 피라졸 및 dlk 억제제로서의 용도 | |
KR100710402B1 (ko) | 3환식 축합 이항환 화합물, 그 제조법 및 그것을 함유하는의약 | |
KR20150132170A (ko) | 야누스 키나제 억제제로서의 비-시클릭 시아노에틸피라졸로 피리돈 | |
AU2018334272A1 (en) | Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors | |
CN113518779B (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
CN113825757B (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
TW202128690A (zh) | 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 | |
EP3459953B1 (en) | Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative | |
WO2006098519A1 (ja) | ピラゾロピリミジン誘導体またはその医学上許容される塩 | |
WO2006016715A1 (ja) | ピラゾロ[1,5-a]ピリミジン誘導体 | |
CN116715658A (zh) | 苯并环酮类衍生物调节剂、其制备方法和应用 | |
TWI823255B (zh) | 作為Wee-1抑制劑的稠環化合物 | |
CN115884776A (zh) | 杂环大环化合物及其医药用途 | |
WO2022166810A1 (zh) | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 | |
CN106045966B (zh) | 取代杂环化合物及其在药物上的应用 | |
TW202214655A (zh) | 氧雜氮雜雙環類衍生物、其製備方法及其在醫藥上的應用 | |
CN116693510A (zh) | 二氢苯并呋喃类化合物、其制备方法及其在医药上的应用 | |
EP4190789A1 (en) | Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof | |
CN116354932A (zh) | 嘧啶衍生物及其制备方法和用途 | |
WO2020207352A1 (zh) | 三嗪酮并咪唑类化合物及其医药用途 | |
CN116635377A (zh) | 己酮糖激酶抑制剂及其用途 | |
CN113444110A (zh) | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680008527.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007508262 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006223818 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7007/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2601717 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006729844 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006223818 Country of ref document: AU Date of ref document: 20060317 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006223818 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077023817 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006729844 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0608722 Country of ref document: BR Kind code of ref document: A2 Effective date: 20070914 |